Literature DB >> 6976861

Immune complexes in early arthritis. L Detection of immune complexes before rheumatoid arthritis is definite.

V E Jones, R K Jacoby, T Wallington, P Holt.   

Abstract

Fifty-three patients with early arthritis were studied longitudinally for up to 3 years. During this time, 24 developed sufficient features for definite rheumatoid arthritis (RA) to be diagnosed. The other (arthralgia patients) differed from the RA patients as, in the majority, C-reactive protein and ESR were normal and anti-nuclear antibodies or rheumatoid factors were rarely found. Moreover, in time their signs and symptoms improved or disappeared. Circulating immune complexes were detected in both groups of patients by the platelet aggregation test whereas complexes detected by abnormal Clq-binding activity were found mainly in the RA patients. Platelet-aggregating complexes were usually present in the first samples studied and disappeared in the arthralgia patients with recovery from their symptoms. In the RA patients, Clq-binding complexes appeared simultaneously or later than platelet-aggregating complexes but both tests were positive several months before RA could be diagnosed. These results suggest that immune complexes are one of the first immunological abnormalities to appear in patients with arthritis. Although the constituent antigen and antibody of complexes detected by either test are unknown, their possible nature is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6976861      PMCID: PMC1537321     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Analysis of the components of immune complexes.

Authors:  D Male; I M Roitt
Journal:  Mol Immunol       Date:  1979-03       Impact factor: 4.407

2.  Platelet aggregation and cryo-IgM in the study of hepatitis and immune complex states.

Authors:  K Penttinen; O Wager; J A Räsänen; G Myllylä; E Haapanen
Journal:  Clin Exp Immunol       Date:  1973-11       Impact factor: 4.330

3.  Circulating immune complexes in Mycoplasma pneumoniae infection.

Authors:  G Biberfeld; R Norberg
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

4.  Role of platelets in immune-complex-induced aggregation of human blood platelets.

Authors:  G Myllylä
Journal:  Ann Med Exp Biol Fenn       Date:  1973

5.  Reactive arthritis associated with Campylobacter jejuni enteritis.

Authors:  J H Berden; H L Muytjens; L B van de Putte
Journal:  Br Med J       Date:  1979-02-10

6.  Immune complexes and the evolution of Lyme arthritis. Dissemination and localization of abnormal C1q binding activity.

Authors:  J A Hardin; A C Steere; S E Malawista
Journal:  N Engl J Med       Date:  1979-12-20       Impact factor: 91.245

7.  The pathogenesis of arthritis associated with viral hepatitis. Complement-component studies.

Authors:  E Alpert; K J Isselbacher; P H Schur
Journal:  N Engl J Med       Date:  1971-07-22       Impact factor: 91.245

8.  Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes.

Authors:  R S Amos; T J Constable; R A Crockson; A P Crockson; B McConkey
Journal:  Br Med J       Date:  1977-01-22

9.  Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome.

Authors:  A T Masi; J A Maldonado-Cocco; S B Kaplan; S L Feigenbaum; R W Chandler
Journal:  Semin Arthritis Rheum       Date:  1976-05       Impact factor: 5.532

10.  Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up.

Authors:  R K Jacoby; M I Jayson; J A Cosh
Journal:  Br Med J       Date:  1973-04-14
View more
  9 in total

1.  Genes associated with rheumatoid arthritis and mild inflammatory arthritis. I. Major histocompatibility complex class I, II, and III allotypes.

Authors:  A H Puttick; D C Briggs; K I Welsh; R Vaughan; E A Williamson; M Boyce; R K Jacoby; V E Jones
Journal:  Ann Rheum Dis       Date:  1990-04       Impact factor: 19.103

2.  Human parvovirus infection in early rheumatoid and inflammatory arthritis.

Authors:  B J Cohen; M M Buckley; J P Clewley; V E Jones; A H Puttick; R K Jacoby
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

3.  C1q-bearing immune complexes detected by a monoclonal antibody to human C1q in rheumatoid arthritis sera and synovial fluids.

Authors:  U Antes; H P Heinz; D Schultz; D Brackertz; M Loos
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

4.  Complement activating properties of complexes containing rheumatoid factor in synovial fluids and sera from patients with rheumatoid arthritis.

Authors:  C J Elson; S D Carter; B J Cottrell; D G Scott; P A Bacon; T B Wallington
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

Review 5.  B lymphocytes and humoral immune responses in rheumatoid arthritis.

Authors:  L S De Clerck
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

6.  Synovial synthesis of rheumatoid factors and immune complex constituents in early arthritis.

Authors:  V Jones; P C Taylor; R K Jacoby; T B Wallington
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

7.  The complement fixing properties and class distribution of rheumatoid factors (antiglobulins) in rheumatoid arthritis and other diseases.

Authors:  R E March; J S Reeback; E J Holborow; V E Jones; R K Jacoby
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

8.  Anti-globulins and circulating complexes in early rheumatoid arthritis.

Authors:  F C Hay; A Young; M G Jones; L J Nineham; D K Male; I M Roitt
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

9.  Immune complexes in early arthritis. II. Immune complex constituents are synthesized in the synovium before rheumatoid factors.

Authors:  V E Jones; R K Jacoby; P J Cowley; C Warren
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.